Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic International (NASDAQ:DYAI), a biotechnology company, announced its participation in significant investor and industry events in February and March 2021. CEO Mark Emalfarb will present at the BIO CEO & Investor Conference (Feb 16-18) and HC Wainwright Global Life Sciences (Mar 9-10). David A. Zarling, PhD, will discuss COVID-19 therapies at the 28th International Molecular Med Tri-Con (Feb 17). The 33rd Annual Roth Conference will also feature a presentation by Emalfarb (Mar 15-17). Investors can schedule one-on-one meetings via email or through event platforms.
Dyadic International (NASDAQ:DYAI) announced the appointment of Patrick Lucy to its Board of Directors, effective January 8, 2021. The board has been expanded from six to seven members. Patrick brings over 29 years of biotechnology experience and is expected to enhance the company's strategic efforts to commercialize its C1 gene expression platform. CEO Mark Emalfarb expressed excitement over Patrick's involvement, citing his extensive background in biopharmaceuticals, including successful partnerships worth over $1.5 billion. This new addition aims to improve healthcare accessibility and affordability globally.
Dyadic International, Inc. (NASDAQ:DYAI) has announced an interview with CEO Mark Emalfarb on FOX Business Network's The Claman Countdown on December 9, 2020, at 3:15 PM ET. The discussion will highlight the company’s proprietary C1 gene expression platform, aimed at reducing production costs and enhancing the efficacy of biologic vaccines and drugs. Dyadic is focused on advancing its biopharmaceutical technology and expanding its market opportunities to improve healthcare access and affordability.
On November 12, 2020, Dyadic International (NASDAQ:DYAI) reported its financial results for Q3 2020, highlighting a solid cash position of $30.5 million and six new collaborations in animal and human health. Despite a net loss of $2.5 million, compared to $1.7 million a year prior, R&D revenue slightly decreased to $416,000. The company announced significant advancements in its COVID-19 programs, working with multiple research institutions. Collaborative efforts in the Asia Pacific region are expanding, notably with Jiangsu Hengrui Medicine, enhancing Dyadic's market presence.
Dyadic International, Inc. (NASDAQ:DYAI) announced it will release its financial results for Q3 2020 on November 12, 2020, after market close. A conference call will follow on the same day at 5:00 p.m. ET to discuss the results. Dyadic focuses on enhancing its proprietary C1 expression system for biologic vaccines and drugs, aiming to lower production costs and improve performance. The company is exploring various biopharmaceutical collaborations and research initiatives, especially in the context of increasing healthcare demands due to an aging population.
Dyadic International (NASDAQ:DYAI) updates on its COVID-19 initiatives, reporting significant achievements with its C1 gene expression platform. The company successfully expressed a SARS-CoV-2 monoclonal antibody and has reached a record production level of 3 g/l in just five days. Collaborations are ongoing, including ten animal trials by seven groups. Dyadic has also entered a non-exclusive technology agreement with Epygen Biotech of India to produce clinical trial materials. The C1 platform aims to enhance vaccine and drug production efficiency, potentially addressing global demand.
Dyadic International, Inc. (NASDAQ:DYAI) announced a collaboration with Jiangsu Hengrui Medicine Co., Ltd. to utilize its proprietary C1 gene expression platform for the development of selected biologic drugs. CEO Mark Emalfarb emphasized the partnership's potential to enhance biomanufacturing efficiency at reduced costs, catering to global demand for vaccines and drugs. Hengrui's R&D President, Dr. Lianshan Zhang, expressed the aim to leverage Dyadic's technology for more cost-effective biotherapeutics production. The collaboration demonstrates C1's capability in drug development and manufacturing.
Dyadic International, Inc. (NASDAQ:DYAI) has announced its participation in several upcoming investor and industry events in September 2020. Key presentations include the H.C. Wainwright Conference on September 14, BPI East on September 22, and the Sidoti & Company Conference on September 23. Additionally, Dyadic will present at the World Vaccine Congress on September 29 and October 1, focusing on its proprietary C1 gene expression platform. This platform aims to enhance the development and production of biologic vaccines and drugs. For further details, visit Dyadic's website.
Dyadic International (NASDAQ:DYAI) announced significant advancements and collaborations in both human and animal health sectors as of August 13, 2020. This includes collaborations with top pharmaceutical companies and initiation of SARS-CoV-2 vaccine trials. The company reported $11.8 million in cash and equivalents, up from $4.8 million at year-end 2019, with a research revenue increase to $524,000. Despite a net loss of $2.65 million for the quarter, Dyadic remains well-positioned financially, filing an S-3 registration for a $50 million stock offering to enhance capital resources.
Dyadic International (NASDAQ:DYAI) announced significant advancements on August 13, 2020, including a fully funded collaboration with a top five global pharmaceutical company for COVID-19 therapeutics. The company is also conducting animal trials for its SARS-CoV-2 vaccine candidate, with promising results. Dyadic's financial position remains strong, with approximately $11.8 million in cash and a $50 million At The Market offering program filed. The company has also expanded its R&D collaborations, reflecting its growing portfolio and potential in the biotechnology market.